25.8
Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's…
Insulin preparations, based on their duration of action, are categorized as short-acting and long-acting.
Short-acting regular insulin forms hexamers, slowing its absorption, and is given 30-45 minutes before a meal. In contrast, short-acting insulin analogs like lispro, aspart, and glulisine are injected just before meals. They dissociate into monomers, resulting in quicker absorption and rapid action.
An intermediate-acting NPH contains an insulin suspension complexed with zinc and protamine, which, upon administration, dissolves gradually, prolonging its action up to 10-20 hours.
In comparison, long-acting analogs, such as glargine, detemir, and degludec, provide extended insulin coverage and lower hypoglycemia risk.
Typically, pens or needle-free jet injectors subcutaneously inject an insulin preparation.
Also, continuous subcutaneous insulin infusion pumps deliver only short-acting insulins, improving glucose control overnight, between meals, and during exercise.
Additionally, intravenous infusions of regular insulin regulate glucose in diabetic ketoacidosis patients and during perioperative procedures.
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between short-acting and long-acting insulin preparations?
Short-acting insulins work rapidly and are divided into regular insulin and rapid-acting analogs like lispro, aspart, and glulisine. Regular insulin forms hexamers, slowing absorption and requiring injection 30-45 minutes before meals. Rapid-acting analogs dissociate into monomers for quicker absorption and are injected just before meals. Long-acting insulins, such as glargine, detemir, and degludec, provide extended 24-hour coverage with lower hypoglycemia risk.
Q2: How do insulin analogs modify absorption compared to regular insulin?
Insulin analogs alter human insulin's amino acid sequence or protein structure while retaining insulin receptor binding ability. This structural modification changes how the insulin behaves in solution and after injection. Rapid-acting analogs like lispro and aspart are absorbed more rapidly from subcutaneous sites, have lower hypoglycemia rates, and show slightly improved A1c levels compared to regular insulin.
Q3: Why does NPH insulin have a prolonged duration of action?
NPH insulin is a complex of native insulin with zinc and protamine that dissolves gradually after subcutaneous injection, extending its action up to 10-20 hours. This gradual dissolution prolongs insulin availability in the bloodstream. NPH is typically administered once or twice daily, often combined with short-acting insulin for comprehensive glucose management.
Q4: What delivery methods are used for insulin administration?
Insulin is primarily administered subcutaneously via prefilled pen devices or needle-free jet injectors. Continuous subcutaneous insulin infusion pumps deliver only short-acting insulins, improving glucose control overnight, between meals, and during exercise. Intravenous infusions of regular insulin are used to regulate glucose in diabetic ketoacidosis patients and during perioperative procedures when rapid insulin action is needed.
Q5: How does insulin glargine achieve extended coverage compared to NPH?
Insulin glargine provides more predictable 24-hour coverage with lower hypoglycemia risk than NPH insulin. Due to its acidic pH, glargine forms aggregates upon subcutaneous injection, causing prolonged absorption and steady insulin release. This smoother, more consistent action profile makes glargine a preferred long-acting option for maintaining baseline insulin levels throughout the day.
Q6: What are the advantages of insulin detemir and degludec over earlier long-acting insulins?
Insulin detemir has a smoother time-action profile and reduced hypoglycemia prevalence compared to NPH insulin. Insulin degludec forms multihexamers post-injection, leading to less severe hypoglycemia than glargine. Both analogs offer improved safety profiles and more predictable glucose control, making them effective options for long-term diabetes management.
Q7: Why can't long-acting insulins be administered intravenously?
Long-acting insulins like glargine, detemir, and degludec are designed for prolonged subcutaneous absorption through specific formulation strategies such as aggregation or complex formation. Due to their specific absorption and action profiles, these insulins cannot be given intravenously, intramuscularly, or through infusion devices. Only regular short-acting insulin is suitable for intravenous administration in acute care settings.